21 CFR 11.100 sets three general requirements for electronic signatures: each one unique to one individual and never reassigned, identity verified before a signature is assigned, and a certification to FDA that the signatures are the legally binding equivalent of handwritten ones. All three belong in the URS and the site procedure.
A picture of a signature pasted into a PDF is neither a handwritten nor an electronic signature under 21 CFR Part 11: nothing in it is unique to the person, verified or linked to the record. EU GMP Annex 11 (2011 text) expects the same link. Sign on controlled paper, or in a system that binds signature to record.
21 CFR Part 11 and EU GMP Annex 11 overlap on validation, access control and audit trails but differ in emphasis: Part 11 on electronic signatures, Annex 11 on a risk-based system lifecycle. Fixing the destination market in the design basis means the URS and validation plan for BMS, EMS and SCADA are written once.
Environmental monitoring and BMS data that support GMP decisions must meet ALCOA+. In practice that means individual logins, time-synchronized controllers, an audit trail users cannot disable, alarms acknowledged with name and comment, and tested backups, with GMP-critical parameters separated early onto a validated system.
In today’s pharmaceutical manufacturing environment, operational efficiency is no longer just about maximizing output — it must also align with strict GMP compliance, product quality, and…
How Does an MES Work in Pharmaceutical Manufacturing? A Manufacturing Execution System (MES) acts as the digital backbone of pharmaceutical production, bridging enterprise planning systems and shop floor operations. It ensures that every…